Leede Financial Has Positive View of TSE:ONC FY2025 Earnings

Oncolytics Biotech Inc. (TSE:ONC - Free Report) - Stock analysts at Leede Financial increased their FY2025 earnings per share estimates for shares of Oncolytics Biotech in a research note issued on Wednesday, July 9th. Leede Financial analyst D. Loe now forecasts that the company will earn ($0.37) per share for the year, up from their previous estimate of ($0.40). The consensus estimate for Oncolytics Biotech's current full-year earnings is ($0.41) per share. Leede Financial also issued estimates for Oncolytics Biotech's FY2026 earnings at ($0.39) EPS, FY2027 earnings at ($0.36) EPS, FY2028 earnings at ($0.36) EPS and FY2029 earnings at ($0.25) EPS.

Separately, Jones Trading cut Oncolytics Biotech from a "strong-buy" rating to a "hold" rating in a report on Friday, May 16th.

Oncolytics Biotech Stock Performance

Shares of TSE ONC traded up C$0.02 during midday trading on Friday, hitting C$1.62. 134,412 shares of the stock traded hands, compared to its average volume of 140,375. The firm has a 50-day moving average of C$0.82 and a two-hundred day moving average of C$0.93. The firm has a market capitalization of C$124.86 million, a P/E ratio of -4.51 and a beta of 1.35. The company has a debt-to-equity ratio of 11.75, a quick ratio of 8.86 and a current ratio of 2.99. Oncolytics Biotech has a one year low of C$0.44 and a one year high of C$2.08.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.